Clinical Benefit to an Aurora a Kinase Inhibitor in a Patient With Metastatic Integrase Interactor 1‐Deficient Carcinoma

Oncologist - United States
doi 10.1634/theoncologist.2018-0279
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Alphamed Press

Related search

VHL Loss Predicts Response to Aurora Kinase a Inhibitor in Renal Cell Carcinoma Cells

Molecular Medicine Reports
OncologyGeneticsMolecular BiologyBiochemistryCancer ResearchMolecular Medicine
2018English

Aurora Kinase a (AURKA; Aurora-A)

Science-Business eXchange
2012English

Clinical Outcome of Third-Line Pazopanib in a Patient With Metastatic Renal Cell Carcinoma

Case Reports in Oncological Medicine
Oncology
2015English

Marked Leukemoid Reaction in a Patient With Metastatic Breast Carcinoma

American Journal of Hematology
Hematology
2017English

A Phase I Study of BI 811283, an Aurora B Kinase Inhibitor, in Patients With Advanced Solid Tumors

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2016English

Antitumor Activity of MLN8054, an Orally Active Small-Molecule Inhibitor of Aurora a Kinase

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2007English

Cyclin-Dependent Kinase Inhibitor-1-Deficient Mice Are Susceptible to Osteoarthritis Associated With Enhanced Inflammation

Journal of Bone and Mineral Research
EndocrinologyOrthopedicsSports MedicineMetabolismDiabetes
2017English

Metastatic Adamantinoma Responds to Treatment With Receptor Tyrosine Kinase Inhibitor

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2010English

Targeting Hepatocarcinogenesis Model in C56BL6 Mice With Pan-Aurora Kinase Inhibitor Danusertib

Journal of Cancer
Oncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy